


Anti-Phospho-PIM1 (Tyr309) Polyclonal Antibody

Product Details

Ig Type:	IgG
Reactivity:	Human,Mouse,Rat
Conjugation:	Unconjugated
Molecular Weight:	Actual: 45 kDa.
Purification:	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.

Applications

Verified Activity: 1. Western blot analysis of extracts from HUVEC cells treated with PMA using Pim-1 (Phospho-Tyr309) Antibody TMAC-03298. The lane on the right is treated with the antigen-specific peptide.



Application:	WB
Recommended	WB: 1:500-1000

Properties

Stability & Storage:	Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Peptide sequence around phosphorylation site of tyrosine 309(H-R-Y(p)-H-G) derived from Human Pim-1
Antigen Species:	human
Uniprot ID:	P11309
Synonyms:	p-PIM1 (Tyr309);PIM1 (p-Tyr309);PIM1 (p-Y309);p-PIM1 (Y309)

Research Background

Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis. Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3). Phosphorylation of MYC leads to an increase of MYC protein stability

and thereby an increase of transcriptional activity. The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481